# Calcium Channel Blockade in Primary Aldosteronism

> **NCT04179019** · PHASE2 · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 15 (actual)

## Conditions studied

- Primary Aldosteronism
- Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)

## Interventions

- **DRUG:** Amlodipine

## Key facts

- **NCT ID:** NCT04179019
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-01
- **Primary completion:** 2023-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04179019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04179019, "Calcium Channel Blockade in Primary Aldosteronism". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04179019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*